Hydroxyurea in the sickle cell disease modern era
Expert Review of Clinical Pharmacology · 2024-09 · 17 (9) · 777-791
DOI: 10.1080/17512433.2024.2390915 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 20.08.2024. Verfasst von Chazmyn Riley und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hydroxyurea, Antisickling Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
INTRODUCTION: Sickle cell disease is an inherited disorder characterized by hemoglobin S polymerization leading to vaso-occlusion and hemolytic anemia. These result in a variety of pathological events, causing both acute and chronic complications. Millions around the world are affected by sickle cell disease with predominance in sub-Saharan Africa. Hydroxyurea was the first drug approved for use in sickle cell disease to reduce the occurrence of painful crises and blood transfusions in patients with frequent, moderate to severe painful crises. AREAS COVERED: With the development of new therapeutics, the role of hydroxyurea is evolving. This narrative review aims to provide clinical data, safety information, and supplementary evidence for the role of hydroxyurea in the current era of sickle cell disease. A comprehensive literature search of databases, including PubMed and Cochrane Library, was conducted from 1963 to 2024. EXPERT OPINION: Even though new medications have been approved for sickle cell disease, hydroxyurea remains the gold standard. Hydroxyurea is not only a disease modifier but it has additional clinical benefits, it is affordable, and its longevity has prompted expanded research in areas such as underutilization and pharmacogenomics. As the treatment landscape evolves, hydroxyurea's long-standing record of efficacy and safety continues to support its role as a key agent in disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
- Lisa Dean Moseley Institute Foundation for Cancer and Blood Disorders, Nemours Children's Hospital, Wilmington, DE, USA.
ORCID-Profile: Chazmyn Riley, Walter K Kraft
Förderung
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Riley, C., Kraft, W. K., & Miller, R. (2024). Hydroxyurea in the sickle cell disease modern era. Expert Review of Clinical Pharmacology, 17(9), 777-791. https://doi.org/10.1080/17512433.2024.2390915
Vancouver
Riley C, Kraft WK, Miller R. Hydroxyurea in the sickle cell disease modern era. Expert Review of Clinical Pharmacology. 2024;17(9):777-791. doi:10.1080/17512433.2024.2390915
BibTeX
@article{Riley2024,
author = {Riley, Chazmyn and Kraft, Walter K and Miller, Robin},
title = {Hydroxyurea in the sickle cell disease modern era},
journal = {Expert Review of Clinical Pharmacology},
year = {2024},
volume = {17},
number = {9},
pages = {777--791},
doi = {10.1080/17512433.2024.2390915}
}
EUVIMED